Oral immunization with a Streptococcal pneumoniae polysaccharide conjugate vaccine in enterocoated microparticles induces serum antibodies against type specific polysaccharides

Vaccine

Volumn 17, Issue 1, 1999, Pages 72-81

  Flanagan, Michael P ^a   Michael, J Gabriel ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Microencapsulation; Oral immunization; Polysaccharide specific responses

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OUTER MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE; SECRETORY IMMUNOGLOBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; IMMUNIZATION; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; MICROENCAPSULATION; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CAPSULES; INJECTIONS, INTRAPERITONEAL; INTESTINAL ABSORPTION; INTESTINE, SMALL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; STOMACH; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0032889092     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00118-2     Document Type: Article

References (49)

1. Lee C.-J., Wang T.R. Pneumococcal infection and immunization in children. Crit. Rev. Microbiol. 20:1994;1-12.
2. Stool S.E., Field M.J. The impact of otitis media. Pediatr. Infect. Dis. J. 8:1989;S11-S14.
3. Wandstrat T.L., Kaplan B. Pharmacoeconomic impact of factors affecting compliance with antibiotics affecting compliance with antibiotic regimens in the treatment of acute otitis media. Pediatr. Infect. Dis. J. 16:1997;S27-S29.
4. Plouffe J.F., Breiman R.F., Facklam R.R. Bacteremia with Streptococcus pneumoniae in adults - implications for therapy and prevention. JAMA. 275:1996;194-198.
5. Bennet N.M., Buffington J., LaForce F.M. Pneumococcal bacteremia in Monroe County, New York. Am. J. Public Health. 82:1992;1513-1516.
6. Hook E.W., Horton C.A., Schaberg D.R. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA. 249:1983;1055-1057.
7. Dowell S.F., Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am. Fam. Physician. 55:1997;1647-1654.
8. Kaplan S.L. The emergence of resistant pneumococcus as a pathogen in childhood upper respiratory tract infections. Semin. Respir. Infect. 10:1995;31-36.
9. Duchin J.S., Breiman R.F., Diamond A.et al. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. Pediatr. Infect. Dis. J. 14:1995;745-750.
10. MacLeod C.M., Hodges R.G., Heidelberger M.et al. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82:1945;445-465.
11. Smit P., Oberholzer D., Hayden-Smith S.et al. Protective efficacy of pneumococcal vaccines. JAMA. 238:1977;2613-2616.
12. Borgono J.M., Mclean A.A., Vella P.P.et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc. Soc. Exp. Biol. Med. 157:1978;148-154.
13. Otqvist A, Hedlund J, Burnam L-A et al. and The Swedish Pneumococcal Vaccination Study Group. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998, 351, 399-403.
14. Hirschmann J.V., Lipsky B.A. The pneumococcal vaccine after 15 years of use. Arch. Intern. Med. 154:1994;373-377.
15. Bisgard K.M., Wenger J.D. Recommendations for the use of Haemophilus influenza type b vaccines among children in the United States. Pediatr. Ann. 26:1997;361-365.
16. Ahman H., Kayhty H., Tamminen P., Vuorela A., Malinoski F., Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr. Infect. Dis. J. 15:1996;134-139.
17. Pichichero M.E., Shelly M.A., Treanor J.J. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr. Infect. Dis. J. 16:1997;72-74.
18. Flanagan M.P., Wang C., Michael J.G. Characterization of the immune response following oral administration of modified antigen in an adjuvant-free system. J. Immunol. 150:1993;35.
19. Jain S.L., Barone K.S., Michael J.G. Activation patterns of murine T cells after oral administration of an enterocoated soluble antigen. Cell Immunol. 167:1996;170-175.
20. Jain S.L., Barone K.S., Michael J.G. Activation patterns of murine B cells after 0ral administration of an encapsulated soluble antigen. Vaccine. 14:1996;1291-1297.
21. Flanagan M.P., Battisti G., Michael J.G. Oral administration of Escherichia coli in enteric coated microparticles induces serum antibodies against lipopolysaccharide antigens. J. Endotox. Res. 3:1996;481-489.
22. Vella P.P., Marburg S., Staub J.M.et al. Immunogenicity of conjugate vaccines consisting of Pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a Meningococcal outer membrane protein complex. Infect. Immun. 60:1992;4977-4983.
23. Koskela M. Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr. Infect. Dis. J. 6:1987;519-526.
24. Brown R.L., Gibson J.A., Sladen G.E., Hicks B., Dawson A.M. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut. 15:1974;631-641.
25. Davis S.S., Hardy J.G., Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut. 27:1986;886-892.
26. Giebink G.S., Koskella M., Vella P.P., Harris M., Le C.T. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J. Infect. Dis. 167:1993;347-355.
27. Paton J.C., Tbogood I.R., Cockington R.A., Hansman D. Antibody response to pneumococcal vaccine in children aged 5 to 15 years. Am. J. Dis. Child. 140:1986;135-138.
28. Mosier D., Subbarao B. Thymus-independent antigens: complexity of B-lymphocyte activation revealed. Immunol. Today. 3:1982;217-222.
29. van-den-Dobbelsteen G.P.J.M., van-Rees E.P. Mucosal immune responses to pneumococcal polysaccharides: implications for vaccination. Trends Microbiol. 3:1995;155-159.
30. Melnick J.L. Current status of poliovirus infections. Clin. Microbiol. Rev. 9:1996;293-300.
31. Levine, M.M., Ferreccio, C., Black, R.E. and Germanier, R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric coated capsule formulation. Lancet 1987, 9 May, 1049-1052.
32. Lycke N., Hellstrom U., Holmgren J. Circulating cholera antitoxin memory cells in the blood one year after oral cholera vaccination in humans. Scand. J. Immunol. 26:1987;207-211.
33. Waldman R.H., Stone J., Bergmann K.et al. Secretory antibody following oral influenza immunization. Am. J. Med. Sci. 292:1986;367-371.
34. McGhee J.R., Mestecky J. In defense of mucosal surfaces - development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect. Dis. Clin. North Am. 4:1990;315-341.
35. McGhee J.R., Mestecky J., Dertzbaugh M., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 10:1992;75-88.
36. McGhee J.R., Kiyono H. New perspectives in vaccine development: mucosal immunity to infections. Infect. Agents Dis. 2:1993;55-73.
37. Litwin A., Flanagan M., Entis G.et al. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral delivery. Ann. Allergy Asthma Immunol. 77:1996;132-138.
38. Litwin A., Flanagan M., Entis G., Gottschlich G., Esch R., Gartside P., Michael J.G. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double blind study. J. Allergy Clin. Immunol. 100:1997;30-38.
39. Donnelly J.J., Deck R.R., Liu M.A. Immunogenicity of a Haemophilus influenza polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J. Immunol. 145:1990;3071-3079.
40. Liu M.A., Friedman A., Oliff A.I.et al. A vaccine derived from Neisseria meningitidis with mitogenic activity for lymphocytes. Proc. Natl Acad. Sci. 89:1992;4633-4637.
41. Ambrosino D.M., Bolon D., Collard H., Van Etten R., Kanchana M.V., Finberg R.W. Effect of Haemophilus influenza polysaccharide outer membrane protein complex conjugate vaccine on macrophages. J. Immunol. 149:1992;3978-3983.
42. Santosham M., Wolff M., Reed R.et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenza type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N. Engl. J. Med. 324:1991;1767-1772.
43. Snapper C.M., Rosas F.R., Kehry M.R., Mond J.J., Wetzler L.M. Neisseria porins may provide critical second signals to polysaccharide-activated murine B cells for induction of immunoglobulin secretion. Infect. Immun. 65:1997;3203-3208.
44. Lett E., Klopfenstein C., Klein J.-P., Scholler M., Wachsmann D. Mucosal immunogenicity of polysaccharides conjugated to a peptide or multiple-antigen peptide containing T- and B-cell epitopes. Infect. Immun. 63:1995;2645-2651.
45. Holmgren J., Czerkinsky C., Lycke N., Svennerholm A. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am. J. Trop. Med. Hygiene. 50:1994;42-54.
46. Lycke N., Holmgren J. Mucosal immune response to cholera toxin - basis of memory and adjuvant action. Monographs in Allergy. 24:1988;274-281.
47. Van Cott J.L., Kobayashi T., Yamamoto M., Pillai S., McGhee J.R., Kiyono H. Induction of pneumococcal polysaccharide-specific mucosal immune responses by oral immunization. Vaccine. 14:1996;392-398.
48. van-den-Dobbelsteen GPJM, Brunekreef K, Kroes H, Sminia T, van-Rees EP. Ontogeny of the mucosal immune response against different types of pneumococcal polysaccharides in the rat. Adv Mucosal Immunol 1995, 415-419.
49. Berquist C., Lagergard T., Linblad M., Holmgren J. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect. Immun. 63:1995;2021-2025.